Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- pitolisant
- Pradaxa (dabigatran)
Interactions between your drugs
dabigatran pitolisant
Applies to: Pradaxa (dabigatran), pitolisant
GENERALLY AVOID: Coadministration with inducers of P-glycoprotein (P-gp) may significantly reduce the bioavailability of dabigatran following oral administration of dabigatran etexilate, which is a substrate of the efflux transporter. When a single dose of dabigatran etexilate was administered following pretreatment with the P-gp inducer rifampin (600 mg once daily for 7 days), dabigatran peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately two-thirds compared to the reference treatment. Dabigatran exposure was close to normal seven days after cessation of rifampin.
MANAGEMENT: Concomitant use of dabigatran with P-gp inducers should generally be avoided.
References (5)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2008) "Product Information. Pradax (dabigatran)." Boehringer Ingelheim (Canada) Ltd
- (2010) "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim
- Randhawa J, Thiruchelvam N, Ghobrial M, et al. (2014) "Practical recommendations on incorporating new oral anticoagulants into routine practice." Clin Adv Hematol Oncol, 12, p. 675-83
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Xywav
Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients ...
Adderall
Adderall (amphetamine and dextroamphetamine) is used to treat narcolepsy and ADHD. Includes side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Concerta
Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity ...
Ritalin
Ritalin (methylphenidate) is used to treat attention deficit disorder (ADD) and narcolepsy ...
Armodafinil
Armodafinil may be used to improve wakefulness in adults who are very sleepy due to narcolepsy ...
Amphetamine
Amphetamine is a stimulant and is used to trat narcolepsy and attention deficit disorder. Includes ...
Amphetamine/dextroamphetamine
Amphetamine/dextroamphetamine is used for ADHD, fatigue, narcolepsy
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.